Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C

PLoS One. 2017 Jun 14;12(6):e0179094. doi: 10.1371/journal.pone.0179094. eCollection 2017.

Abstract

Type I interferons (IFNs) play an important role in antiviral immunity as well as immunopathogenesis of diverse chronic viral infections. However, the precise mechanisms regulating the multifaceted effects of type I IFNs on the immune system and pathological inflammation still remain unclear. In order to assess the immunological dynamics associated with rapid viral clearance in chronic hepatitis C patients during the acute phase of type I IFN therapy, we analyzed multiple parameters of virological and immunological responses in a cohort of 59 Korean hepatitis C patients who received pegylated IFN-α and ribavirin (IFN/RBV). Most of the Korean patients had favorable alleles in the IFN-λ loci for responsiveness to IFN/RBV (i.e., C/C in rs12979860, T/T in rs8099917, and TT/TT in rs368234815). Rapid virological response (RVR) was determined mainly by the hepatitis C virus genotype. Among the cytokines analyzed, higher plasma levels of IL-17A and FGF were observed in non-RVR patients infected with viral genotype 1 and IP-10 was consistently elevated in RVR group infected with genotype 2 during the early phase of antiviral therapy. In addition, these three cytokines were correlated each other, suggesting a functional linkage of the cytokines in antiviral responses during IFN/RBV therapy. A low baseline frequencies of regulatory T cells and γδ T cells, but high level of group 2 innate lymphoid cells, in peripheral bloods were also significantly associated with the RVR group, implicating a potential role of the cellular immunity during the early phase of IFN/RBV therapy. Therefore, the immunological programs established by chronic hepatitis C and rapid disruption of the delicate balance by exogenous type I IFN might be associated with the subsequent virological outcomes in chronic hepatitis C patients.

MeSH terms

  • Aged
  • Antiviral Agents / administration & dosage*
  • Antiviral Agents / pharmacology
  • Drug Therapy, Combination
  • Female
  • Gene Expression Regulation / drug effects
  • Genotype
  • Hepacivirus / genetics
  • Hepacivirus / physiology*
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / immunology
  • Hepatitis C, Chronic / virology
  • Humans
  • Interferon Type I / administration & dosage*
  • Interferon Type I / pharmacology
  • Interleukins / genetics*
  • Male
  • Middle Aged
  • Prospective Studies
  • Republic of Korea
  • Ribavirin / administration & dosage*
  • Ribavirin / pharmacology
  • Treatment Outcome
  • Viral Load

Substances

  • Antiviral Agents
  • Interferon Type I
  • Interleukins
  • Ribavirin

Grants and funding

This study was supported by grants from the SNUH Research Fund (800-20140047, 800-20140048) and the National Research Foundation of Korea (NRF) funded by the Korean government (MEST; 2013R1A2A2A01007299). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.